MARKET

BHC

BHC

Bausch Health Companies Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

28.86
-0.61
-2.07%
After Hours: 28.61 -0.25 -0.87% 16:17 09/24 EDT
OPEN
29.17
PREV CLOSE
29.47
HIGH
29.46
LOW
28.62
VOLUME
1.95M
TURNOVER
--
52 WEEK HIGH
34.80
52 WEEK LOW
14.86
MARKET CAP
10.36B
P/E (TTM)
-8.0211
1D
5D
1M
3M
1Y
5Y
Turner Syndrome Market: Industry Insights By Growth, Emerging Trends And Forecast By 2028
Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers a detailed overview of the turner syndrome drug market in terms of market segmentation by type, drug type, therapy type and by end-user.
AmericaNewsHour · 2d ago
Top Stocks To Buy Today? 4 Health Care Stocks For Your Watchlist
StockMarket.com · 2d ago
Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?
Zacks.com · 4d ago
CANADA STOCKS-Toronto shares jump as Trudeau win lifts stimulus hopes
reuters.com · 5d ago
Global Sterile Injectable Drugs Market Growth to be Propelled by Increasing R&D Initiatives to Witness Considerable GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 5d ago
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030
Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region.
AmericaNewsHour · 6d ago
Global Sterile Injectable Drugs Market to Witness Considerable growth throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 6d ago
DiGeorge Syndrome Drug Market Propelled by Increased Patient Pool and R&D Initiatives to Witness Substantial GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the DiGeorge syndrome drug market in terms of market segmentation by therapy type, route of administration, end-user, and by region.
AmericaNewsHour · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHC. Analyze the recent business situations of Bausch Health Companies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHC stock price target is 36.08 with a high estimate of 55.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 524
Institutional Holdings: 264.68M
% Owned: 73.77%
Shares Outstanding: 358.81M
TypeInstitutionsShares
Increased
116
21.23M
New
48
5.89M
Decreased
111
12.95M
Sold Out
40
4.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
Joseph Papa
Chief Financial Officer/Executive Vice President
Sam Will
Corporate Executive
Thomas Appio
Corporate Executive
Joseph Gordon
Corporate Executive
Robert Spurr
Executive Vice President/General Counsel
Christina Ackermann
Executive Vice President
Paul Herendeen
Lead Director
Thomas Ross
Independent Director
Richard De Schutter
Independent Director
Brett Icahn
Independent Director
Argeris Karabelas
Independent Director
Sarah Kavanagh
Independent Director
Steven Miller
Independent Director
John Paulson
Independent Director
Robert Power
Independent Director
Russel Robertson
Independent Director
Andrew von Eschenbach
Independent Director
Amy Wechsler
Declaration Date
Dividend Per Share
Ex-Div Date
09/22/2010
Dividend USD 16.77
09/23/2010
05/05/2010
Dividend USD 0.095
05/31/2010
02/24/2010
Dividend USD 0.09
03/04/2010
11/04/2009
Dividend USD 0.09
11/30/2009
08/06/2009
Dividend USD 0.09
08/28/2009
05/06/2009
Dividend USD 0.09
05/13/2009
02/26/2009
Dividend USD 0.375
03/06/2009
11/06/2008
Dividend USD 0.375
12/19/2008
08/13/2008
Dividend USD 0.375
08/21/2008
05/08/2008
Dividend USD 0.375
05/20/2008
03/13/2008
Dividend USD 0.375
03/25/2008
11/08/2007
Dividend USD 0.375
11/16/2007
08/08/2007
Dividend USD 0.375
08/16/2007
05/10/2007
Dividend USD 0.375
05/17/2007
03/15/2007
Dividend USD 0.375
03/22/2007
12/06/2006
Dividend USD 0.5
01/08/2007
11/09/2006
Dividend USD 0.125
11/20/2006
08/03/2006
Dividend USD 0.0775
08/15/2006
05/11/2006
Dividend USD 0.125
05/18/2006
03/23/2006
Dividend USD 0.125
04/05/2006
About BHC
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Webull offers kinds of Bausch Health Companies Inc stock information, including NYSE:BHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHC stock methods without spending real money on the virtual paper trading platform.